Skip to content

Low Molecular Weight Heparin

Overview

Low molecular weight heparin (LMWH) represents a major advance in anticoagulation therapy, offering predictable pharmacokinetics, convenient administration, and improved safety profiles compared to unfractionated heparin (UFH). Derived through controlled depolymerization of UFH, these fragments retain potent anticoagulant activity while exhibiting enhanced bioavailability and reduced binding to plasma proteins and cells. Since their introduction in the 1980s, LMWHs have revolutionized the prevention and treatment of venous thromboembolism, management of acute coronary syndromes, and numerous other thrombotic conditions. Their ability to be administered subcutaneously without routine monitoring has shifted anticoagulation from inpatient to outpatient settings, fundamentally changing clinical practice.

Structure and Biochemistry

Molecular Characteristics

LMWHs are heterogeneous mixtures of glycosaminoglycan chains: - Average molecular weight: 4,000-6,000 Daltons (vs. 12,000-15,000 for UFH) - Chain length: 13-22 saccharide units - Polydispersity: Variable depending on preparation method - Critical pentasaccharide: Present in only 15-25% of chains - Sulfation pattern: Highly variable, affecting activity

Production Methods

Different depolymerization techniques yield distinct products:

Enoxaparin (Clexane/Lovenox): - Benzylation and alkaline hydrolysis - Average MW: 4,500 Daltons - Anti-Xa:Anti-IIa ratio: 3.8:1

Dalteparin (Fragmin): - Nitrous acid depolymerization - Average MW: 6,000 Daltons - Anti-Xa:Anti-IIa ratio: 2.5:1

Tinzaparin (Innohep): - Heparinase digestion - Average MW: 6,500 Daltons - Anti-Xa:Anti-IIa ratio: 1.9:1

Nadroparin (Fraxiparine): - Nitrous acid depolymerization - Average MW: 4,500 Daltons - Anti-Xa:Anti-IIa ratio: 3.5:1

Mechanism of Action

Antithrombin-Mediated Inhibition

LMWHs exert anticoagulant effects through antithrombin (AT):

Factor Xa Inhibition: - Requires only pentasaccharide binding to AT - Conformational change in AT - 1000-fold acceleration of Xa inhibition - Primary anticoagulant mechanism - All LMWH chains with pentasaccharide active

Thrombin (Factor IIa) Inhibition: - Requires chain length ≥18 saccharides - Must bridge AT to thrombin - Only 25-50% of LMWH chains sufficient - Less thrombin inhibition than UFH - Contributes to improved safety profile

Additional Mechanisms

Tissue factor pathway inhibitor (TFPI) Release: - From endothelial cells - Enhances anticoagulant effect - Sustained elevation with LMWH - May contribute to anti-cancer effects

Other Effects: - von Willebrand factor release - Platelet factor 4 binding (reduced vs UFH) - Complement activation (minimal) - Lipase release (less than UFH)

Pharmacology

Pharmacokinetics

Absorption: - Bioavailability: >90% subcutaneous - Peak levels: 3-5 hours post-injection - Steady state: After 2-3 doses - Consistent absorption: Independent of dose

Distribution: - Volume of distribution: Close to blood volume - Protein binding: Minimal, predictable - Cellular binding: Reduced vs UFH - Placental transfer: Minimal to none

Metabolism and Elimination: - Primary route: Renal excretion - Half-life: 3-6 hours (dose-independent) - Clearance: First-order kinetics - Accumulation: In renal impairment

Pharmacodynamics

Predictable Response: - Linear dose-response relationship - Weight-based dosing accurate - Minimal inter-patient variability - No routine monitoring needed

Anti-Xa Activity: - Peak: 3-5 hours post-dose - Duration: 12-24 hours - Correlates with clinical efficacy - Used when monitoring required

Clinical Applications

Venous Thromboembolism Prevention

Orthopedic Surgery: - High-risk procedures: Hip/knee replacement - Extended prophylaxis: Up to 35 days - Superior to UFH: Efficacy and convenience - Dosing examples: - Enoxaparin: 30 mg SC q12h or 40 mg daily - Dalteparin: 5,000 units daily

General Surgery: - Risk stratification: Caprini score - Moderate risk: Lower doses - High risk: Standard therapeutic doses - Duration: Until ambulatory

Medical Prophylaxis: - Hospitalized patients: Acute illness - Padua prediction score: Risk assessment - Standard regimens**: - Enoxaparin: 40 mg daily - Dalteparin: 5,000 units daily

Venous Thromboembolism Treatment

Deep Vein Thrombosis/Pulmonary Embolism: - First-line therapy: Outpatient treatment possible - Bridge to warfarin: Traditional approach - Monotherapy: Until direct oral anticoagulants - Treatment dosing: - Enoxaparin: 1 mg/kg q12h or 1.5 mg/kg daily - Dalteparin: 200 units/kg daily

Cancer-Associated Thrombosis: - Preferred over warfarin: CLOT trial - Extended monotherapy: 3-6 months - Dose adjustment: For thrombocytopenia - Recent challenges: DOACs emerging role

Acute Coronary Syndromes

STEMI: - EXTRACT-TIMI 25: Established benefit - With fibrinolysis: Superior to UFH - Primary PCI: Alternative to UFH - Dosing**: Age and renal adjustment critical

NSTE-ACS: - Multiple trials: Consistent benefit - Reduced bleeding: Compared to UFH - Transition to PCI: No additional anticoagulant - Standard approach: Until definitive therapy

Special Indications

Pregnancy: - Drug of choice: No placental transfer - Thromboprophylaxis: High-risk pregnancies - Treatment doses: For established VTE - Mechanical valves: Controversial, requires expertise

Hemodialysis: - Alternative to UFH: Single bolus dosing - Reduced bleeding: Some studies - Circuit patency: Maintained - Monitoring: Anti-Xa if needed

Bridge Therapy: - Perioperative: Warfarin interruption - High-risk patients: Mechanical valves, recent VTE - Protocols: Institution-specific - Timing: Critical for safety

Monitoring

When Monitoring is Needed

Routine monitoring NOT required, except: - Extremes of weight: <50 kg or >150 kg - Renal impairment: CrCl <30 mL/min - Pregnancy: Changing physiology - Pediatrics: Limited data - Prolonged therapy: Accumulation concerns

Anti-Xa Assay

Methodology: - Chromogenic substrate assay - Measures residual Xa activity - Calibrated with LMWH standards - Product-specific curves ideal

Target Levels: - Prophylactic: 0.2-0.5 IU/mL - Therapeutic q12h: 0.5-1.0 IU/mL - Therapeutic daily: 1.0-2.0 IU/mL - Timing: 4 hours post-dose (peak)

Limitations: - Poor standardization between labs - Uncertain correlation with outcomes - Not widely available - Expensive

Advantages Over UFH

Clinical Advantages

Efficacy: - Equal or superior to UFH - More predictable anticoagulation - Less heparin resistance - Better bioavailability

Safety: - Lower HIT risk: 10-fold reduction - Reduced bleeding: Some studies - Less 03 Spaces/Medical Hub/📝 Exam Prep/Medicine Notebook/Osteoporosis: Long-term use - Minimal 03 Spaces/Medical Hub/📝 Exam Prep/Medicine Notebook/Thrombocytopenia

Practical Advantages

Administration: - Subcutaneous only - Fixed or weight-based dosing - Once or twice daily - Outpatient therapy possible

Monitoring: - Not routinely required - No aPTT monitoring - Cost savings - Improved quality of life

Specific LMWH Preparations

Enoxaparin

Most extensively studied LMWH: - Indications: Broadest FDA approvals - Dosing flexibility: Daily or twice daily - Renal adjustment: CrCl <30 mL/min - Prefilled syringes: Convenient - Generic availability: Cost-effective

Dalteparin

Preferred in specific populations: - Cancer patients: Extended treatment - Renal impairment: Less accumulation - HIT history: Some evidence of safety - Single daily dosing: Most indications

Tinzaparin

Unique characteristics: - Highest molecular weight - Once daily: All indications - Less renal dependence: Theoretical - Not US available: Limited experience

Reversal of LMWH

Challenges in Reversal

  • No specific antidote available
  • Protamine partially effective
  • Anti-Xa activity persists
  • Clinical outcomes uncertain

Protamine Sulfate

Mechanism: - Neutralizes negatively charged LMWH - More effective for anti-IIa activity - Limited effect on anti-Xa activity - 60-80% neutralization maximum

Dosing: - 1 mg per 100 anti-Xa units (if <8 hours) - 0.5 mg per 100 units (if >8 hours) - Maximum: 50 mg - Slow infusion: Prevent reactions

Alternative Approaches

Adverse Effects

Bleeding Complications

Major Bleeding: - Incidence: 1-3% (treatment doses) - Risk factors: Age, renal function, concurrent medications - Sites: GI, retroperitoneal, intracranial - Management: Supportive, consider reversal

Minor Bleeding: - More common: 5-10% - Injection site bruising - Epistaxis, gingival bleeding - Usually doesn't require intervention

Heparin-Induced Thrombocytopenia

Lower Risk than UFH: - Incidence: <1% (vs 1-5% UFH) - Still requires vigilance - Platelet monitoring controversial - Cross-reactivity possible

Management if HIT: - Discontinue immediately - Alternative anticoagulation - Avoid all heparins - Confirm with testing

Other Adverse Effects

Local Reactions: - Injection site pain - Ecchymosis common - Rare skin necrosis - Rotate injection sites

Systemic Effects: - Osteoporosis: Less than UFH - Hyperkalemia: Aldosterone suppression - Elevated transaminases: Usually benign - Allergic reactions: Rare

Special Populations

Renal Impairment

Pharmacokinetic Changes: - Prolonged half-life - Drug accumulation - Increased bleeding risk - Anti-Xa monitoring considered

Dosing Adjustments: - CrCl 30-50: Consider monitoring - CrCl <30: Reduce dose or frequency - Dialysis: Complex considerations - Alternative agents: May be preferred

Obesity

Challenges: - Limited data >150 kg - Dosing controversies - Capping doses debated - Monitoring considered

Approaches: - Use actual body weight - Monitor anti-Xa if >150 kg - No dose capping prophylaxis - Consider alternatives if extreme

Pregnancy

Advantages: - No placental transfer - No teratogenicity - Extensive experience - Reversible effects

Special Considerations: - Increased volume distribution - Accelerated clearance - Consider monitoring - Neuraxial anesthesia timing

Elderly

Considerations: - Reduced renal function common - Increased bleeding risk - Drug interactions - Fall risk assessment

Modifications: - Calculate CrCl - Start conservatively - Monitor closely - Consider prophylactic doses

Drug Interactions

Increased Bleeding Risk

Antiplatelet Agents: - Aspirin: Use cautiously - Clopidogrel: Monitor closely - NSAIDs: Avoid if possible - GP IIb/IIIa inhibitors: Established protocols

Other Anticoagulants: - Overlap during transitions - Bridge therapy protocols - Careful timing essential - Monitor if combined

Other Interactions

Perioperative Management

Preoperative Cessation

  • Prophylactic dose: 12 hours prior
  • Therapeutic dose BID: 24 hours prior
  • Therapeutic dose daily: 24 hours prior
  • High bleeding risk: Consider 48 hours

Neuraxial Anesthesia

Safety Guidelines: - Strict timing requirements - Delay after LMWH dose - Catheter removal timing - Postoperative restart

ASRA Guidelines: - Prophylactic: 12 hours after dose - Therapeutic: 24 hours after dose - Remove catheter before next dose - Wait 4 hours after removal to restart

Postoperative Resumption

  • Hemostasis confirmation
  • Bleeding risk assessment
  • Usually 6-24 hours
  • Modified doses initially

Cost-Effectiveness

Economic Considerations

  • Higher drug cost than UFH
  • Reduced monitoring costs
  • Shorter hospital stays
  • Outpatient treatment savings
  • Generic availability improving

Quality of Life

  • Home administration
  • Reduced clinic visits
  • Predictable dosing
  • Less lifestyle disruption
  • Patient preference

Future Directions

New Developments

  • Biosimilar LMWHs: Increasing availability
  • Ultra-LMWH: Smaller fragments
  • Oral delivery: Research ongoing
  • Reversal agents: Specific antidotes

Evolving Role

  • Competition from DOACs
  • Niche populations remaining
  • Cancer patients
  • Pregnancy
  • Renal failure

Clinical Pearls

References